ZimVie Reports Fourth Quarter and Full Year 2024 Financial Results
ZimVie (NASDAQ: ZIMV) reported its Q4 and FY2024 financial results, marking a transformational year as a pure-play dental company. Full-year 2024 third-party net sales reached $449.7 million, down 1.6% from 2023, with a net loss of $(33.8) million. The company achieved an Adjusted EBITDA of $60.0 million with a 13.3% margin.
In Q4 2024, third-party net sales were $111.5 million, decreasing 1.4% year-over-year, with a net loss of $(9.7) million. However, this represented a $12.5 million improvement from Q4 2023's loss. The quarter's Adjusted EBITDA reached $18.4 million, with a 16.5% margin, showing a 420 basis points increase.
Notable achievements include reducing net debt by over $290 million, streamlining operations through corporate cost reduction, and implementing manufacturing efficiency initiatives. Despite softer end markets, the company improved its Adjusted EBITDA margins by over 4 percentage points in Q4 2024 compared to Q4 2023.
ZimVie (NASDAQ: ZIMV) ha riportato i risultati finanziari per il quarto trimestre e l'anno fiscale 2024, segnando un anno di trasformazione come azienda esclusivamente dentale. Le vendite nette di terzi per l'intero anno 2024 hanno raggiunto i 449,7 milioni di dollari, in calo dell'1,6% rispetto al 2023, con una perdita netta di $(33,8) milioni. L'azienda ha ottenuto un EBITDA rettificato di 60,0 milioni di dollari con un margine del 13,3%.
Nel Q4 2024, le vendite nette di terzi sono state di 111,5 milioni di dollari, con una diminuzione dell'1,4% rispetto all'anno precedente, e una perdita netta di $(9,7) milioni. Tuttavia, ciò ha rappresentato un miglioramento di 12,5 milioni di dollari rispetto alla perdita del Q4 2023. L'EBITDA rettificato del trimestre ha raggiunto i 18,4 milioni di dollari, con un margine del 16,5%, mostrando un aumento di 420 punti base.
Tra i risultati notevoli ci sono la riduzione del debito netto di oltre 290 milioni di dollari, la razionalizzazione delle operazioni attraverso la riduzione dei costi aziendali e l'implementazione di iniziative di efficienza produttiva. Nonostante i mercati finali più deboli, l'azienda ha migliorato i suoi margini EBITDA rettificati di oltre 4 punti percentuali nel Q4 2024 rispetto al Q4 2023.
ZimVie (NASDAQ: ZIMV) reportó sus resultados financieros del cuarto trimestre y del año fiscal 2024, marcando un año transformador como empresa exclusivamente dental. Las ventas netas de terceros del año completo 2024 alcanzaron los 449,7 millones de dólares, una disminución del 1,6% en comparación con 2023, con una pérdida neta de $(33,8) millones. La compañía logró un EBITDA ajustado de 60,0 millones de dólares con un margen del 13,3%.
En el Q4 2024, las ventas netas de terceros fueron de 111,5 millones de dólares, disminuyendo un 1,4% interanual, con una pérdida neta de $(9,7) millones. Sin embargo, esto representó una mejora de 12,5 millones de dólares en comparación con la pérdida del Q4 2023. El EBITDA ajustado del trimestre alcanzó los 18,4 millones de dólares, con un margen del 16,5%, mostrando un aumento de 420 puntos básicos.
Logros notables incluyen la reducción de la deuda neta en más de 290 millones de dólares, la optimización de operaciones a través de la reducción de costos corporativos y la implementación de iniciativas de eficiencia en la fabricación. A pesar de los mercados finales más suaves, la compañía mejoró sus márgenes de EBITDA ajustados en más de 4 puntos porcentuales en el Q4 2024 en comparación con el Q4 2023.
ZimVie (NASDAQ: ZIMV)는 2024년 4분기 및 회계연도 재무 결과를 발표하며, 순수 치과 회사로서의 변혁의 해를 기념했습니다. 2024년 전체 제3자 순매출은 4억 4,970만 달러에 달하며, 이는 2023년 대비 1.6% 감소한 수치로, 순손실은 $(3,380만) 달러였습니다. 회사는 6천만 달러의 조정 EBITDA를 달성했으며, 마진은 13.3%에 달했습니다.
2024년 4분기에는 제3자 순매출이 1억 1,150만 달러로, 전년 대비 1.4% 감소했으며, 순손실은 $(970만) 달러였습니다. 그러나 이는 2023년 4분기의 손실에서 1,250만 달러 개선된 수치입니다. 이번 분기의 조정 EBITDA는 1,840만 달러에 달하며, 마진은 16.5%로 420 베이시스 포인트 증가했습니다.
주목할 만한 성과로는 2억 9천만 달러 이상의 순부채 감소, 기업 비용 절감을 통한 운영 효율화, 제조 효율성 이니셔티브의 구현이 있습니다. 시장 환경이 부드러워진 가운데, 회사는 2024년 4분기에서 2023년 4분기 대비 조정 EBITDA 마진을 4%포인트 이상 개선했습니다.
ZimVie (NASDAQ: ZIMV) a annoncé ses résultats financiers pour le quatrième trimestre et l'exercice 2024, marquant une année de transformation en tant qu'entreprise exclusivement dentaire. Les ventes nettes de tiers pour l'année entière 2024 ont atteint 449,7 millions de dollars, en baisse de 1,6 % par rapport à 2023, avec une perte nette de $(33,8) millions. L'entreprise a réalisé un EBITDA ajusté de 60,0 millions de dollars avec une marge de 13,3 %.
Au Q4 2024, les ventes nettes de tiers se sont élevées à 111,5 millions de dollars, en baisse de 1,4 % par rapport à l'année précédente, avec une perte nette de $(9,7) millions. Cependant, cela représente une amélioration de 12,5 millions de dollars par rapport à la perte du Q4 2023. L'EBITDA ajusté du trimestre a atteint 18,4 millions de dollars, avec une marge de 16,5 %, montrant une augmentation de 420 points de base.
Parmi les réalisations notables, on peut citer la réduction de la dette nette de plus de 290 millions de dollars, la rationalisation des opérations grâce à la réduction des coûts d'entreprise et la mise en œuvre d'initiatives d'efficacité de fabrication. Malgré des marchés finaux plus faibles, l'entreprise a amélioré ses marges d'EBITDA ajustées de plus de 4 points de pourcentage au Q4 2024 par rapport au Q4 2023.
ZimVie (NASDAQ: ZIMV) hat seine finanziellen Ergebnisse für das vierte Quartal und das Geschäftsjahr 2024 veröffentlicht und ein transformierendes Jahr als reines Dentalunternehmen markiert. Die Nettoumsätze von Dritten für das gesamte Jahr 2024 beliefen sich auf 449,7 Millionen Dollar, was einem Rückgang von 1,6% im Vergleich zu 2023 entspricht, mit einem Nettoverlust von $(33,8) Millionen. Das Unternehmen erzielte ein bereinigtes EBITDA von 60,0 Millionen Dollar mit einer Marge von 13,3%.
Im Q4 2024 betrugen die Nettoumsätze von Dritten 111,5 Millionen Dollar, was einem Rückgang von 1,4% im Jahresvergleich entspricht, mit einem Nettoverlust von $(9,7) Millionen. Dies stellte jedoch eine Verbesserung von 12,5 Millionen Dollar im Vergleich zum Verlust im Q4 2023 dar. Das bereinigte EBITDA des Quartals erreichte 18,4 Millionen Dollar, mit einer Marge von 16,5%, was einem Anstieg von 420 Basispunkten entspricht.
Zu den bemerkenswerten Erfolgen gehören die Reduzierung der Nettoverschuldung um über 290 Millionen Dollar, die Straffung der Abläufe durch Unternehmenskostensenkungen und die Umsetzung von Effizienzinitiativen in der Produktion. Trotz schwächerer Endmärkte verbesserte das Unternehmen seine bereinigten EBITDA-Margen im Q4 2024 um über 4 Prozentpunkte im Vergleich zum Q4 2023.
- Net debt reduced by $290+ million
- Q4 Adjusted EBITDA margin improved 420 basis points to 16.5%
- Full-year Adjusted EBITDA increased $9.2 million to $60.0 million
- Q4 net loss improved by $12.5 million year-over-year
- Full-year net loss improved by $22.2 million
- Q4 net sales declined 1.4% to $111.5 million
- Full-year net sales decreased 1.6% to $449.7 million
- Full-year net loss of $(33.8) million
- Softer end market conditions reported
- Q4 net loss margin of (8.7)%
Insights
ZimVie's Q4 and full-year 2024 results highlight a dramatic financial transformation following its strategic pivot to become a pure-play dental company. While revenue performance was modest with FY2024 third-party net sales declining
The most striking achievement is ZimVie's balance sheet overhaul, reducing net debt by over
Despite facing what management described as a "softer end market," ZimVie delivered impressive margin expansion, with Q4 Adjusted EBITDA margins increasing
The full-year net loss improvement of
Looking forward, ZimVie appears positioned to leverage its streamlined cost structure and focused dental market strategy. While the release mentions 2025 guidance was provided, specific figures weren't included in the excerpt. The key question for investors is whether ZimVie can now pivot from restructuring to growth, particularly as management expresses optimism about long-term dental implant market drivers and the company's positioning in digital solutions.
- FY2024 Third Party Net Sales from Continuing Operations of
$449.7 million - FY2024 Net Loss from Continuing Operations of
$(33.8) million ; Net Loss margin of (7.5% ) - FY2024 Adjusted EBITDA[1] from Continuing Operations of
$60.0 million ; Adjusted EBITDA[1] margin of13.3% - FY2024 GAAP diluted EPS from Continuing Operations of
$(1.23) and adjusted diluted EPS[1] of$0.62
PALM BEACH GARDENS, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter and year ended December 31, 2024. Management will host a corresponding conference call today, February 26, 2025, at 4:30 p.m. Eastern Time.
“2024 was a transformational year for ZimVie. We became a pure play dental company and reshaped our financial profile, reducing net debt[1] by more than
Fourth Quarter 2024 Financial Results: Continuing Operations
Third party net sales for the fourth quarter of 2024 were
Net loss for the fourth quarter of 2024 was
Adjusted net income[1] for the fourth quarter of 2024 was
Basic and diluted EPS were
Adjusted EBITDA[1] for the fourth quarter of 2024 was
Full Year 2024 Financial Results: Continuing Operations
Third party net sales for the full year 2024 were
Net loss for the full year 2024 was
Adjusted net income[1] for the full year 2024 was
Basic and diluted EPS were
Adjusted EBITDA[1] for the full year 2024 was
Full Year 2025 Continuing Operations Financial Guidance:
| Projected Year Ending December 31, 2025 | Guidance | Reported Growth | Constant Currency Growth[2] |
| Net Sales | ( | Flat to | |
| Adjusted EBITDA [2] | |||
| Adjusted EPS[2] |
[1] This is a non-GAAP financial measure. Refer to “Note on Non-GAAP Financial Measures” and the reconciliations in this release for further information.
[2] This is a non-GAAP financial measure for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. Refer to “Forward-Looking Non-GAAP Financial Measures” in this release, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that this forward-looking non-GAAP financial measure may be materially different from the corresponding GAAP financial measure.
Conference Call
ZimVie will host a conference call today, February 26, 2025, at 4:30 p.m. ET to discuss its fourth quarter and full year 2024 financial results. To access the call, please register online at https://investor.zimvie.com/events-presentations/event-calendar. A live and archived audio webcast will also be available on this site.
About ZimVie
ZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.
Note on Non-GAAP Financial Measures
This press release includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.
Net debt is provided in this release for certain periods and is calculated by subtracting cash and cash equivalents on a GAAP basis from the non-current portion of debt on a GAAP basis, as detailed in the reconciliations presented later in this press release.
Sales change information in this release is presented on a GAAP (reported) basis and on a constant currency basis. Constant currency percentage changes exclude the effects of foreign currency exchange rates. They are calculated by translating current and prior-period sales from Continuing Operations at the same predetermined exchange rate. The translated results are then used to determine year-over-year percentage increases or decreases.
Net income (loss) and diluted earnings (loss) per share in this release are presented on a GAAP (reported) basis and on an adjusted basis. Adjusted net income (loss) and adjusted diluted earnings (loss) per share exclude the effects of certain items, which are detailed in the reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures presented later in this press release.
Adjusted EBITDA is a non-GAAP financial measure provided in this release for certain periods and is calculated by excluding certain items from net income (loss) from Continuing Operations on a GAAP basis, as detailed in the reconciliations presented later in this press release. Adjusted EBITDA margin is Adjusted EBITDA divided by third party net sales from Continuing Operations for the applicable period.
Adjusted cost of products sold (excluding intangible asset amortization). adjusted R&D and adjusted SG&A (on an actual basis and as a percentage of sales) are non-GAAP financial measures provided in this presentation for certain periods and are calculated by excluding the effects of certain items from cost of products sold (excluding intangible asset amortization), R&D and SG&A, respectively, on a GAAP basis. as detailed in the reconciliations presented later in this presentation.
Reconciliations of these non-GAAP measures to the most directly comparable GAAP financial measures are included in this press release.
Management uses non-GAAP financial measures internally to evaluate the performance of the business. Additionally, management believes these non-GAAP measures provide meaningful incremental information to investors to consider when evaluating the performance of the company. Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported income, but that do not impact the fundamentals of our operations. The non-GAAP measures enable the evaluation of operating results and trend analysis by allowing a reader to better identify operating trends that may otherwise be masked or distorted by these types of items that are excluded from the non-GAAP measures.
Forward-Looking Non-GAAP Financial Measures
This press release also includes certain forward-looking non-GAAP financial measures for the year ending December 31, 2025. We calculate forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. We have not provided quantitative reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because the excluded items are not available on a prospective basis without unreasonable efforts. For example, the timing of certain transactions is difficult to predict because management’s plans may change. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans, intentions, strategies, or prospects. We generally use the words “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “assumes,” “guides,” “targets,” “forecasts,” “sees,” “seeks,” “should,” “could,” “would,” “predicts,” “potential,” “strategy,” “future,” “opportunity,” “work toward,” “intends,” “guidance,” “confidence,” “positioned,” “design,” “strive,” “continue,” “track,” “look forward to,” “optimistic” and similar expressions to identify forward-looking statements. All statements other than statements of historical or current fact are or may be deemed to be forward-looking statements. Such statements are based upon the current beliefs, expectations, and assumptions of management and are subject to significant risks, uncertainties, and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. These risks, uncertainties and changes in circumstances include, but are not limited to: dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products, including impacts from tariffs; pricing pressures from competitors, customers, dental practices and insurance providers; changes in customer demand for our products and services caused by demographic changes or other factors; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration and foreign government regulators, such as more stringent requirements for regulatory clearance of products; competition; the impact of healthcare reform measures; reductions in reimbursement levels by third-party payors; cost containment efforts sponsored by government agencies, legislative bodies, the private sector and healthcare group purchasing organizations, including the volume-based procurement process in China; control of costs and expenses; dependence on a limited number of suppliers for key raw materials and outsourced activities; the ability to obtain and maintain adequate intellectual property protection; breaches or failures of our information technology systems or products, including by cyberattack, unauthorized access or theft; the ability to retain the independent agents and distributors who market our products; our ability to attract, retain and develop the highly skilled employees we need to support our business; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; a determination by the Internal Revenue Service that the distribution of our shares of common stock by Zimmer Biomet Holdings, Inc. in 2022 (the "distribution") or certain related transactions should be treated as taxable transactions; financing transactions undertaken in connection with the separation and risks associated with additional indebtedness; the impact of the separation on our businesses and the risk that the separation and the results thereof may be more difficult, time consuming and/or costly than expected, which could impact our relationships with customers, suppliers, employees and other business counterparties; restrictions on activities following the distribution in order to preserve the tax-free treatment of the distribution; the ability to form and implement alliances; changes in tax obligations arising from tax reform measures, including European Union rules on state aid, or examinations by tax authorities; product liability, intellectual property and commercial litigation losses; changes in general industry and market conditions, including domestic and international growth rates; changes in general domestic and international economic conditions, including inflation and interest rate and currency exchange rate fluctuations; and the effects of global pandemics and other adverse public health developments on the global economy, our business and operations and the business and operations of our suppliers and customers, including the deferral of elective procedures and our ability to collect accounts receivable. You are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. Forward-looking statements speak only as of the date they are made, and we expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media Contact Information:
ZimVie
Grace Flowers • Grace.Flowers@ZimVie.com
(561) 319-6130
Investor Contact Information:
Gilmartin Group LLC
Webb Campbell • Webb@gilmartinir.com
| ZIMVIE INC. CONSOLIDATED STATEMENT OF OPERATIONS (in thousands, except per share data) | |||||||||||||||
| (unaudited) For the Three Months Ended December 31, | For the Years Ended December 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net Sales | |||||||||||||||
| Third party, net | $ | 111,521 | $ | 113,066 | $ | 449,749 | $ | 457,197 | |||||||
| Related party, net | — | — | — | 236 | |||||||||||
| Total Net Sales | 111,521 | 113,066 | 449,749 | 457,433 | |||||||||||
| Cost of products sold, excluding intangible asset amortization | (38,707 | ) | (42,573 | ) | (162,303 | ) | (166,819 | ) | |||||||
| Related party cost of products sold, excluding intangible asset amortization | — | — | — | (231 | ) | ||||||||||
| Intangible asset amortization | (5,994 | ) | (6,134 | ) | (24,053 | ) | (26,512 | ) | |||||||
| Research and development | (6,621 | ) | (6,893 | ) | (26,905 | ) | (26,162 | ) | |||||||
| Selling, general and administrative | (58,564 | ) | (62,909 | ) | (238,589 | ) | (248,964 | ) | |||||||
| Restructuring and other cost reduction initiatives | (2,017 | ) | 717 | (5,681 | ) | (4,489 | ) | ||||||||
| Acquisition, integration, divestiture and related | (5,948 | ) | (10,548 | ) | (12,882 | ) | (15,195 | ) | |||||||
| Operating expenses | (117,851 | ) | (128,340 | ) | (470,413 | ) | (488,372 | ) | |||||||
| Operating Loss | (6,330 | ) | (15,274 | ) | (20,664 | ) | (30,939 | ) | |||||||
| Other income, net | 2,748 | 1,515 | 8,908 | 326 | |||||||||||
| Interest income | 2,111 | 583 | 7,050 | 2,512 | |||||||||||
| Interest expense | (4,120 | ) | (5,559 | ) | (18,887 | ) | (22,746 | ) | |||||||
| Loss from continuing operations before income taxes | (5,591 | ) | (18,735 | ) | (23,593 | ) | (50,847 | ) | |||||||
| Provision for income taxes from continuing operations | (4,077 | ) | (3,428 | ) | (10,237 | ) | (5,202 | ) | |||||||
| Net Loss from Continuing Operations of ZimVie Inc. | (9,668 | ) | (22,163 | ) | (33,830 | ) | (56,049 | ) | |||||||
| Income (loss) from discontinued operations, net of tax | (2,097 | ) | (312,689 | ) | 8,005 | (337,233 | ) | ||||||||
| Net Loss of ZimVie Inc. | $ | (11,765 | ) | $ | (334,852 | ) | $ | (25,825 | ) | $ | (393,282 | ) | |||
| Basic (Loss) Earnings Per Common Share: | |||||||||||||||
| Continuing operations | $ | (0.35 | ) | $ | (0.83 | ) | $ | (1.23 | ) | $ | (2.12 | ) | |||
| Discontinued operations | (0.08 | ) | (11.76 | ) | 0.29 | (12.75 | ) | ||||||||
| Net Loss | $ | (0.43 | ) | $ | (12.59 | ) | $ | (0.94 | ) | $ | (14.87 | ) | |||
| Diluted (Loss) Earnings Per Common Share | |||||||||||||||
| Continuing operations | $ | (0.35 | ) | $ | (0.83 | ) | $ | (1.23 | ) | $ | (2.12 | ) | |||
| Discontinued operations | (0.08 | ) | (11.76 | ) | 0.29 | (12.75 | ) | ||||||||
| Net Loss | $ | (0.43 | ) | $ | (12.59 | ) | $ | (0.94 | ) | $ | (14.87 | ) | |||
| ZIMVIE INC. CONSOLIDATED BALANCE SHEETS (in thousands, except per share data) | |||||||
| As of December 31, | |||||||
| 2024 | 2023 | ||||||
| ASSETS | |||||||
| Current Assets: | |||||||
| Cash and cash equivalents | $ | 74,974 | $ | 71,511 | |||
| Accounts receivable, net | 65,211 | 65,168 | |||||
| Inventories | 75,018 | 79,600 | |||||
| Prepaid expenses and other current assets | 23,295 | 23,825 | |||||
| Current assets of discontinued operations | 18,787 | 242,773 | |||||
| Total Current Assets | 257,285 | 482,877 | |||||
| Property, plant and equipment, net | 47,268 | 54,167 | |||||
| Goodwill | 257,605 | 262,111 | |||||
| Intangible assets, net | 92,734 | 114,354 | |||||
| Note receivable | 64,643 | — | |||||
| Other assets | 26,611 | 26,747 | |||||
| Noncurrent assets of discontinued operations | 7,528 | 265,089 | |||||
| Total Assets | $ | 753,674 | $ | 1,205,345 | |||
| LIABILITIES AND EQUITY | |||||||
| Current Liabilities: | |||||||
| Accounts payable | $ | 32,958 | $ | 27,785 | |||
| Income taxes payable | 3,263 | 2,863 | |||||
| Other current liabilities | 62,905 | 67,108 | |||||
| Current liabilities of discontinued operations | 34,818 | 75,858 | |||||
| Total Current Liabilities | 133,944 | 173,614 | |||||
| Deferred income taxes | — | 265 | |||||
| Lease liability | 8,218 | 9,080 | |||||
| Other long-term liabilities | 9,232 | 9,055 | |||||
| Non-current portion of debt | 220,451 | 508,797 | |||||
| Noncurrent liabilities of discontinued operations | 122 | 95,041 | |||||
| Total Liabilities | 371,967 | 795,852 | |||||
| Commitments and Contingencies | |||||||
| Stockholders' Equity: | |||||||
| Common stock, | 277 | 271 | |||||
| Preferred stock, | — | — | |||||
| Additional paid in capital | 938,630 | 922,996 | |||||
| Accumulated deficit | (466,639 | ) | (440,814 | ) | |||
| Accumulated other comprehensive loss | (90,561 | ) | (72,960 | ) | |||
| Total Stockholders' Equity | 381,707 | 409,493 | |||||
| Total Liabilities and Stockholders' Equity | $ | 753,674 | $ | 1,205,345 | |||
| ZIMVIE INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) | |||||||
| For the Years Ended December 31, | |||||||
| 2024 | 2023 | ||||||
| Cash flows provided by operating activities: | |||||||
| Net loss of ZimVie Inc. | $ | (25,825 | ) | $ | (393,282 | ) | |
| Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||
| Depreciation and amortization | 34,312 | 121,686 | |||||
| Share-based compensation | 16,592 | 27,020 | |||||
| Deferred income tax provision | (4,243 | ) | (17,088 | ) | |||
| Loss on disposal of fixed assets | 5,518 | 2,996 | |||||
| Other non-cash items | 4,985 | 3,245 | |||||
| Gain on sale of spine disposal group | (11,079 | ) | — | ||||
| Adjustment of spine disposal group to fair value | (11,143 | ) | 289,456 | ||||
| Changes in operating assets and liabilities: | |||||||
| Income taxes | 3,253 | (15,054 | ) | ||||
| Accounts receivable | (4,202 | ) | 21,083 | ||||
| Related party receivables | — | 8,483 | |||||
| Inventories | 6,443 | 25,446 | |||||
| Prepaid expenses and other current assets | (3,015 | ) | 5,340 | ||||
| Accounts payable and accrued liabilities | 8,323 | (24,759 | ) | ||||
| Related party payable | — | (13,176 | ) | ||||
| Other assets and liabilities | (5,745 | ) | (4,248 | ) | |||
| Net cash provided by operating activities | 14,174 | 37,148 | |||||
| Cash flows provided by (used in) investing activities: | |||||||
| Additions to instruments | (1,330 | ) | (5,978 | ) | |||
| Additions to other property, plant and equipment | (5,352 | ) | (6,509 | ) | |||
| Proceeds from sale of spine disposal group, net of cash disposed | 290,918 | — | |||||
| Other investing activities | (1,940 | ) | (2,687 | ) | |||
| Net cash provided by (used in) investing activities | 282,296 | (15,174 | ) | ||||
| Cash flows used in financing activities: | |||||||
| Proceeds from debt | — | 4,760 | |||||
| Payments on debt | (290,000 | ) | (29,304 | ) | |||
| Payments related to tax withholding for share-based compensation | (2,825 | ) | (3,402 | ) | |||
| Proceeds from stock plan activity | 1,872 | 2,280 | |||||
| Business combination contingent consideration payments | (3,712 | ) | — | ||||
| Net cash used in financing activities | (294,665 | ) | (25,666 | ) | |||
| Effect of exchange rates on cash and cash equivalents | (13,001 | ) | 1,859 | ||||
| Decrease in cash and cash equivalents | (11,196 | ) | (1,833 | ) | |||
| Cash and cash equivalents, beginning of year | 87,768 | 89,601 | |||||
| Cash and cash equivalents, end of period | $ | 76,572 | $ | 87,768 | |||
| Presentation includes cash of both continuing and discontinued operations | |||||||
RECONCILIATION OF NET DEBT
Continuing Operations ($ in thousands)
| As of December 31, | |||||||
| 2024 | 2023 | ||||||
| Non-current portion of debt | $ | 220,451 | $ | 508,797 | |||
| Less: Cash and cash equivalents | (74,974 | ) | (71,511 | ) | |||
| Net Debt | $ | 145,477 | $ | 437,286 | |||
RECONCILIATION OF CONSTANT CURRENCY NET SALES
Continuing Operations ($ in thousands)
| For the Three Months Ended December 31, | |||||||||||||||
| 2024 | 2023 | Change (%) | Foreign Exchange Impact | Constant Currency % Change | |||||||||||
| United States | $ | 64,402 | $ | 65,383 | (1.5 | %) | 0.0 | % | (1.5 | %) | |||||
| International | 47,119 | 47,683 | (1.2 | %) | (1.2 | %) | (0.0 | %) | |||||||
| Total Dental Third Party Sales | 111,521 | 113,066 | (1.4 | %) | (0.5 | %) | (0.9 | %) | |||||||
| Related Party Net Sales | - | - | 0.0 | % | 0.0 | % | 0.0 | % | |||||||
| Total Dental Net Sales | $ | 111,521 | $ | 113,066 | (1.4 | %) | (0.5 | %) | (0.9 | %) | |||||
| For the Years Ended December 31, | |||||||||||||||
| 2024 | 2023 | Change (%) | Foreign Exchange Impact | Constant Currency % Change | |||||||||||
| United States | $ | 266,816 | $ | 269,557 | (1.0 | %) | 0.0 | % | (1.0 | %) | |||||
| International | 182,933 | 187,640 | (2.5 | %) | (1.0 | %) | (1.5 | %) | |||||||
| Total Dental Third Party Sales | 449,749 | 457,197 | (1.6 | %) | (0.4 | %) | (1.2 | %) | |||||||
| Related Party Net Sales | - | 236 | (100.0 | %) | 0.0 | % | (100.0 | %) | |||||||
| Total Dental Net Sales | $ | 449,749 | $ | 457,433 | (1.7 | %) | (0.4 | %) | (1.3 | %) | |||||
RECONCILIATION OF ADJUSTED NET INCOME AND DILUTED EPS
Continuing Operations (in thousands, except per share data)
| For the Three Months Ended December 31, 2024 | ||||||||||||||||||
| Net Sales | Cost of products sold, excluding intangible asset amortization | Operating expenses, excluding cost of products sold | Operating (Loss) Income | Net (Loss) Income | Diluted EPS | |||||||||||||
| Reported | $ | 111,521 | $ | (38,707 | ) | $ | (79,144 | ) | $ | (6,330 | ) | $ | (9,668 | ) | $ | (0.35 | ) | |
| Restructuring and other cost reduction initiatives [1] | - | - | 2,017 | 2,017 | 2,017 | 0.07 | ||||||||||||
| Acquisition, integration, divestiture and related [2] | - | - | 5,948 | 5,948 | 5,948 | 0.22 | ||||||||||||
| Intangible asset amortization | - | - | 5,994 | 5,994 | 5,994 | 0.22 | ||||||||||||
| European union medical device regulation [3] | - | - | 766 | 766 | 766 | 0.03 | ||||||||||||
| Other charges [4] | - | (289 | ) | - | (289 | ) | (289 | ) | (0.01 | ) | ||||||||
| Litigation settlement [5] | - | - | 1,095 | 1,095 | 1,095 | 0.04 | ||||||||||||
| Share-based compensation modification [6] | - | - | 283 | 283 | 283 | 0.01 | ||||||||||||
| Tax effect of above adjustments & other [7] | - | - | - | - | 1,419 | 0.04 | ||||||||||||
| Adjusted | $ | 111,521 | $ | (38,996 | ) | $ | (63,041 | ) | $ | 9,484 | $ | 7,565 | $ | 0.27 | ||||
| For the Three Months Ended December 31, 2023 | ||||||||||||||||||
| Net Sales | Cost of products sold, excluding intangible asset amortization | Operating expenses, excluding cost of products sold | Operating (Loss) Income | Net (Loss) Income | Diluted EPS | |||||||||||||
| Reported | $ | 113,066 | $ | (42,573 | ) | $ | (85,767 | ) | $ | (15,274 | ) | $ | (22,163 | ) | $ | (0.83 | ) | |
| Restructuring and other cost reduction initiatives [1] | - | - | (717 | ) | (717 | ) | (717 | ) | (0.03 | ) | ||||||||
| Acquisition, integration, divestiture and related [2] | - | - | 10,548 | 10,548 | 10,548 | 0.41 | ||||||||||||
| Intangible asset amortization | - | - | 6,134 | 6,134 | 6,134 | 0.23 | ||||||||||||
| European union medical device regulation [3] | - | - | 347 | 347 | 347 | 0.01 | ||||||||||||
| Other charges [4] | - | 278 | 286 | 564 | 564 | 0.02 | ||||||||||||
| Spin-related share-based compensation expense [8] | - | - | 5,335 | 5,335 | 5,335 | 0.20 | ||||||||||||
| Tax effect of above adjustments & other [7] | - | - | - | - | 2,524 | 0.09 | ||||||||||||
| Adjusted | $ | 113,066 | $ | (42,295 | ) | $ | (63,834 | ) | $ | 6,937 | $ | 2,572 | $ | 0.10 | ||||
| [1] Restructuring activities to better position the organization and the expenses incurred were primarily related to employee termination benefits and professional fees. [2] Acquisition, integration, divestiture and related expenses for the three months ended December 31, 2024 include the write-off of software costs incurred prior to the separation that were determined in the fourth quarter of 2024 to be unusable for ZimVie's current enterprise resource planning software system plans ( [3] Expenses incurred for initial compliance with the European Union (“EU”) Medical Device Regulation (“MDR”) for previously-approved products. [4] Inventory write-offs resulting from restructuring activities and property, plant, and equipment step-up amortization from prior acquisitions. [5] Legal expenses associated with the defense of claims that are outside the ordinary course of business. [6] Net impact to share-based compensation expense of converting outstanding restricted stock units (“RSUs”) with performance-based metrics based on the consolidated results of the spine and dental segments into time-based RSUs following the sale of the spine segment. [7] Reflects the tax effect of the adjustments from reported to adjusted, as well as an adjustment for management’s expectation of ZimVie’s statutory tax rate based on current tax law and adjusted pre-tax income. [8] Spin-related share-based compensation expense from grants provided due to the successful separation from Zimmer Biomet. | ||||||||||||||||||
| For the Year Ended December 31, 2024 | ||||||||||||||||||
| Net Sales | Cost of products sold, excluding intangible asset amortization | Operating expenses, excluding cost of products sold | Operating (Loss) Income | Net (Loss) Income | Diluted EPS | |||||||||||||
| Reported | $ | 449,749 | $ | (162,303 | ) | $ | (308,110 | ) | $ | (20,664 | ) | $ | (33,830 | ) | $ | (1.23 | ) | |
| Restructuring and other cost reduction initiatives [1] | - | - | 5,681 | 5,681 | 5,681 | 0.21 | ||||||||||||
| Acquisition, integration, divestiture and related [2] | - | - | 12,882 | 12,882 | 12,882 | 0.47 | ||||||||||||
| Intangible asset amortization | - | - | 24,053 | 24,053 | 24,053 | 0.88 | ||||||||||||
| European union medical device regulation [3] | - | - | 1,884 | 1,884 | 1,884 | 0.07 | ||||||||||||
| Other charges [4] | - | 1,144 | - | 1,144 | 1,144 | 0.04 | ||||||||||||
| Litigation settlement [5] | - | - | 1,095 | 1,095 | 1,095 | 0.04 | ||||||||||||
| Share-based compensation modification [6] | - | - | (238 | ) | (238 | ) | (238 | ) | (0.01 | ) | ||||||||
| Tax effect of above adjustments & other [7] | - | - | - | - | 4,281 | 0.15 | ||||||||||||
| Adjusted | $ | 449,749 | $ | (161,159 | ) | $ | (262,753 | ) | $ | 25,837 | $ | 16,952 | $ | 0.62 | ||||
| For the Year Ended December 31, 2023 | ||||||||||||||||||
| Net Sales | Cost of products sold, excluding intangible asset amortization | Operating expenses, excluding cost of products sold | Operating (Loss) Income | Net (Loss) Income | Diluted EPS | |||||||||||||
| Reported | $ | 457,433 | $ | (167,050 | ) | $ | (321,322 | ) | $ | (30,939 | ) | $ | (56,049 | ) | $ | (2.12 | ) | |
| Restructuring and other cost reduction initiatives [1] | - | - | 4,489 | 4,489 | 4,489 | 0.17 | ||||||||||||
| Acquisition, integration, divestiture and related [2] | - | - | 15,195 | 15,195 | 15,195 | 0.57 | ||||||||||||
| Intangible asset amortization | - | - | 26,512 | 26,512 | 26,512 | 1.00 | ||||||||||||
| Related party | (236 | ) | 231 | - | (5 | ) | (5 | ) | - | |||||||||
| European union medical device regulation [3] | - | - | 2,574 | 2,574 | 2,574 | 0.10 | ||||||||||||
| Other charges [4] | - | 1,143 | 1,145 | 2,288 | 2,288 | 0.09 | ||||||||||||
| Spin-related share-based compensation expense [8] | - | - | 7,679 | 7,679 | 7,679 | 0.29 | ||||||||||||
| Tax effect of above adjustments & other [7] | - | - | - | - | 3,152 | 0.12 | ||||||||||||
| Adjusted | $ | 457,197 | $ | (165,676 | ) | $ | (263,728 | ) | $ | 27,793 | $ | 5,835 | $ | 0.22 | ||||
| [1] Restructuring activities to better position the organization and the expenses incurred were primarily related to employee termination benefits and professional fees. [2] Acquisition, integration, divestiture and related expenses for the year ended December 31, 2024 include the write-off of software costs incurred prior to the separation that were determined in the fourth quarter of 2024 to be unusable for ZimVie's current enterprise resource planning software system plans ( [3] Expenses incurred for initial compliance with the EU MDR for previously-approved products. [4] Inventory write-offs resulting from restructuring activities and property, plant, and equipment step-up amortization from prior acquisitions. [5] Legal expenses associated with the defense of claims that are outside the ordinary course of business. [6] Net impact to share-based compensation expense of converting outstanding RSUs with performance-based metrics based on the consolidated results of the spine and dental segments into time-based RSUs following the sale of the spine segment. [7] Reflects the tax effect of the adjustments from reported to adjusted, as well as an adjustment for management’s expectation of ZimVie’s statutory tax rate based on current tax law and adjusted pre-tax income. [8] Spin-related share-based compensation expense from grants provided due to the successful separation from Zimmer Biomet. | ||||||||||||||||||
RECONCILIATION OF ADJUSTED EBITDA:
Continuing Operations ($ in thousands)
| For the Three Months Ended December 31, | For the Years Ended December 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net Sales | |||||||||||||||
| Total Third Party Sales | $ | 111,521 | $ | 113,066 | $ | 449,749 | $ | 457,197 | |||||||
| Related Party Sales | - | - | - | 236 | |||||||||||
| Total Net Sales | $ | 111,521 | $ | 113,066 | $ | 449,749 | $ | 457,433 | |||||||
| Net Loss | $ | (9,668 | ) | $ | (22,163 | ) | $ | (33,830 | ) | $ | (56,049 | ) | |||
| Interest expense, net | 2,009 | 4,976 | 11,837 | 20,234 | |||||||||||
| Income tax provision | 4,077 | 3,428 | 10,237 | 5,202 | |||||||||||
| Depreciation and amortization | 8,358 | 7,908 | 33,168 | 34,507 | |||||||||||
| EBITDA | 4,776 | (5,851 | ) | 21,412 | 3,894 | ||||||||||
| Share-based compensation | 4,118 | 9,316 | 15,879 | 23,476 | |||||||||||
| Restructuring and other cost reduction initiatives [1] | 2,017 | (717 | ) | 5,681 | 4,489 | ||||||||||
| Acquisition, integration, divestiture and related [2] | 5,948 | 10,548 | 12,882 | 15,195 | |||||||||||
| Related party gain | - | - | - | (5 | ) | ||||||||||
| European Union medical device regulation [3] | 766 | 347 | 1,884 | 2,574 | |||||||||||
| Litigation settlement [4] | 1,095 | - | 1,095 | - | |||||||||||
| Other charges [5] | (289 | ) | 278 | 1,144 | 1,143 | ||||||||||
| Adjusted EBITDA | $ | 18,431 | $ | 13,921 | $ | 59,977 | $ | 50,766 | |||||||
| Net Loss Margin [6] | ( | ) | ( | ) | ( | ) | ( | ) | |||||||
| Adjusted EBITDA Margin [7] | 16.5% | 12.3% | 13.3% | 11.1% | |||||||||||
| [1] Restructuring activities to better position our organization for future success based on the current business environment and sale of the spine business, primarily related to employee termination benefits and professional fees. [2] Acquisition, integration, divestiture and related expenses for the three months and year ended December 31, 2024 include the write-off of software costs incurred prior to the separation that were determined in the fourth quarter of 2024 to be unusable for ZimVie's current enterprise resource planning software system plans ( [3] Expenses incurred for initial compliance with the EU MDR for previously-approved products. [4] Legal expenses associated with the defense of claims that are outside the ordinary course of business. [5] Inventory write-offs resulting from restructuring activities and property, plant, and equipment step-up amortization from prior acquisitions. [6] Net Loss Margin is calculated as Net Loss divided by third party net sales for the applicable period. [7] Adjusted EBITDA Margin is Adjusted EBITDA divided by third party net sales for the applicable period. | |||||||||||||||
RECONCILIATION OF ADJUSTED COST OF PRODUCTS SOLD (excluding intangible asset amortization), R&D and SG&A:
Continuing Operations ($ in thousands)
| Three Months Ended December 31, | Percentage of Third Party Net Sales | Years Ended December 31, | Percentage of Third Party Net Sales | |||||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | |||||||||||||||||||||
| Cost of products sold, excluding intangible asset amortization | $ | (38,707 | ) | $ | (42,573 | ) | (34.7 | %) | (37.7 | %) | $ | (162,303 | ) | $ | (166,819 | ) | (36.1 | %) | (36.5 | %) | ||||||||
| Other charges [1] | (289 | ) | 278 | (0.3 | %) | 0.3 | % | 1,144 | 1,143 | 0.3 | % | 0.3 | % | |||||||||||||||
| Adjusted cost of products sold, excluding intangible asset amortization | $ | (38,996 | ) | $ | (42,295 | ) | (35.0 | %) | (37.4 | %) | $ | (161,159 | ) | $ | (165,676 | ) | (35.8 | %) | (36.2 | %) | ||||||||
| 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | |||||||||||||||||||||
| Research and development | $ | (6,621 | ) | $ | (6,893 | ) | (5.9 | %) | (6.1 | %) | $ | (26,905 | ) | $ | (26,162 | ) | (6.0 | %) | (5.7 | %) | ||||||||
| European union medical device regulation [2] | 766 | 347 | 0.7 | % | 0.3 | % | 1,884 | 2,574 | 0.4 | % | 0.5 | % | ||||||||||||||||
| Share-based compensation modification [3] | 21 | - | 0.0 | % | 0.0 | % | (25 | ) | - | 0.0 | % | 0.0 | % | |||||||||||||||
| Spin-related share-based compensation expense [4] | - | 80 | 0.0 | % | 0.1 | % | - | 320 | 0.0 | % | 0.1 | % | ||||||||||||||||
| Adjusted research and development | $ | (5,834 | ) | $ | (6,466 | ) | (5.2 | %) | (5.7 | %) | $ | (25,046 | ) | $ | (23,268 | ) | (5.6 | %) | (5.1 | %) | ||||||||
| 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | |||||||||||||||||||||
| Selling, general and administrative | $ | (58,564 | ) | $ | (62,909 | ) | (52.5 | %) | (55.6 | %) | $ | (238,589 | ) | $ | (248,964 | ) | (53.0 | %) | (54.5 | %) | ||||||||
| Other charges [1] | - | 286 | 0.0 | % | 0.3 | % | - | 1,145 | 0.0 | % | 0.3 | % | ||||||||||||||||
| Litigation settlement [5] | 1,095 | - | 1.0 | % | 0.0 | % | 1,095 | - | 0.2 | % | 0.0 | % | ||||||||||||||||
| Share-based compensation modification [3] | 262 | - | 0.2 | % | 0.0 | % | (213 | ) | - | (0.1 | %) | 0.0 | % | |||||||||||||||
| Spin-related share-based compensation expense [4] | - | 5,255 | 0.0 | % | 4.6 | % | - | 7,359 | 0.0 | % | 1.6 | % | ||||||||||||||||
| Adjusted selling, general and administrative | $ | (57,207 | ) | $ | (57,368 | ) | (51.3 | %) | (50.7 | %) | $ | (237,707 | ) | $ | (240,460 | ) | (52.9 | %) | (52.6 | %) | ||||||||
| [1] Inventory write-offs resulting from restructuring activities and property, plant, and equipment step-up amortization from prior acquisitions. [2] Expenses incurred for initial compliance with the EU MDR for previously-approved products. [3] Net impact to share-based compensation expense of converting outstanding RSUs with performance-based metrics based on the consolidated results of the spine and dental segments to time-based RSUs following the sale of the spine segment. [4] Spin-related share-based compensation expense from grants provided due to the successful separation from Zimmer Biomet. [5] Legal expenses associated with the defense of claims that are outside the ordinary course of business. | ||||||||||||||||||||||||||||
FAQ
What were ZimVie's (ZIMV) full-year 2024 financial results?
How much did ZIMV reduce its net debt in 2024?
What was ZimVie's Q4 2024 Adjusted EBITDA margin improvement?
How did ZIMV's Q4 2024 net loss compare to Q4 2023?
What was ZIMV's adjusted diluted EPS for full-year 2024?
